India, Nov. 12 -- Thursday, Absci Corp. (ABSI), a clinical pharmaceutical company, appointed Gerry Muhle as Chief Commercial Officer to lead its commercial strategy and support the development and commercialization of ABS-201 and its broader drug pipeline.
Muhle has over 25 years of commercial leadership experience, including successful product launches and managing major businesses.
He joins Absci from Galderma, where he led global product and commercial strategy across its dermatology, aesthetics, and skincare divisions.
On Nasdaq, the shares are trading 8.10 percent down at $9.30 in pre-market hours. The shares closed Wednesday's regular trading 1.50 percent up.
For comments and feedback contact: editorial@rttnews.com
Published by H...